Trial of Erlotinib in Patients With JAK-2 V617F Positive Polycythemia Vera

Summary

The primary objective of this study is to determine the overall response rate to erlotinib in patients with polycythemia vera (PV). Response rate will be assessed by improvement in the complete blood count, ultrasound of the spleen, and JAK2 molecular status. It is purposed in this study to explore a possible molecular targeting of the driving mechanism of PV.

Timeline

Start

2009-12

Primary completion

2012-12

Completion

2014-02

Outcome

Outcome not reported

Stopped: “The study was terminated by the sponsor”

Drugs

Indications